PT 141 10mg

PT-141 Peptide (Bremelanotide)

PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide derived from the metabolism of Melanotan II. It acts as an agonist at melanocortin receptors, particularly MC3R and MC4R. Unlike Melanotan II, PT-141 was developed to focus on central nervous system effects related to sexual arousal while minimizing peripheral melanotropic (skin pigmentation) activity. It is primarily researched for its potential influence on sexual function through central melanocortin pathways.

Specifications Molecular Formula: C50H68N14O10 Molecular Weight: 1025.18 g/mol Other Known Titles: Bremelanotide

PT-141 Peptide Research

PT-141 and Melanocortin Receptors PT-141 is a potent agonist of melanocortin receptors MC3R and MC4R. MC4R activation in the hypothalamus is associated with regulation of appetite, energy expenditure, and reproductive behaviors. MC3R is thought to modulate these effects and influence metabolic processes. Research suggests that binding to these receptors may stimulate neurons in the hypothalamus and surrounding limbic regions, potentially leading to increased sexual arousal and appetitive sexual behaviors in preclinical models.

PT-141 and Sexual Arousal Preclinical studies in female rodent models have reported that PT-141 administration increases solicitation behaviors (appetitive sexual behavior) without significantly altering lordosis or general motor activity. These effects were observed following both peripheral and central (intracerebroventricular or medial preoptic area) administration. Researchers hypothesize that PT-141 may activate dopamine terminals in the medial preoptic area, contributing to its pro-sexual effects.

In male models, PT-141 and related melanocortin agonists have been linked to increased cavernosal pressure through neuronal release of nitric oxide (NO) via the NO-cGMP pathway. These effects were blocked by MC3R/MC4R antagonists and NOS inhibitors, supporting a central melanocortin-mediated mechanism.

PT-141 and Central Nervous System Functional neuroimaging and psychometric studies have explored PT-141’s effects on brain processing of sexual stimuli. In women with hypoactive sexual desire disorder, MC4R agonism was associated with increased activity in cerebellar and supplementary motor areas, deactivation of the secondary somatosensory cortex during erotic stimuli, and enhanced connectivity between the amygdala and insula. These changes correlated with elevated sexual desire scores lasting up to 24 hours in some assessments.

Important Disclaimer The products mentioned are intended strictly for laboratory research and in-vitro experimentation. They are not for human or animal consumption. Bodily introduction is strictly prohibited. All information provided is for educational purposes only and does not constitute medical advice. Always refer to our terms and conditions.

This product is strictly for research/laboratory use only. Human or animal use and/or consumption is strictly prohibited by law. Only qualified and licensed professionals should handle these products. Any information found on this site is strictly for educational purposes only. Refer to our terms and conditions for more details.

References

1. Pfaus, J., Giuliano, F., & Gelez, H. (2007). Bremelanotide: an overview of preclinical CNS effects on female sexual function. The journal of sexual medicine, 4 Suppl 4, 269–279. https://doi.org/10.1111/j.1743-6109.2007.00610.x
2. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9941379, Bremelanotide. https://pubchem.ncbi.nlm.nih.gov/compound/Bremelanotide
3. Molinoff, P. B., Shadiack, A. M., Earle, D., Diamond, L. E., & Quon, C. Y. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96–102. https://doi.org/10.1111/j.1749-6632.2003.tb03167.x
4. Renquist, B. J., Lippert, R. N., Sebag, J. A., Ellacott, K. L., & Cone, R. D. (2011). Physiological roles of the melanocortin MC₃ receptor. European journal of pharmacology, 660(1), 13–20. https://doi.org/10.1016/j.ejphar.2010.12.025
5. Adan, R. A., Tiesjema, B., Hillebrand, J. J., la Fleur, S. E., Kas, M. J., & de Krom, M. (2006). The MC4 receptor and control of appetite. British journal of pharmacology, 149(7), 815–827. https://doi.org/10.1038/sj.bjp.0706929
6. Pfaus, J. G., Shadiack, A., Van Soest, T., Tse, M., & Molinoff, P. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 101(27), 10201–10204. https://doi.org/10.1073/pnas.0400491101
7. Vemulapalli, R., Kurowski, S., Salisbury, B., Parker, E., & Davis, H. (2001). Activation of central melanocortin receptors by MT-II increases cavernosal pressure in rabbits by the neuronal release of NO. British journal of pharmacology, 134(8), 1705–1710. https://doi.org/10.1038/sj.bjp.0704437
8. Thurston, L., Hunjan, T., Mills, E. G., Wall, M. B., Ertl, N., Phylactou, M., Muzi, B., Patel, B., Alexander, E. C., Suladze, S., Modi, M., Eng, P. C., Bassett, P. A., Abbara, A., Goldmeier, D., Comninos, A. N., & Dhillo, W. S. (2022). Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. The Journal of clinical investigation, 132(19), e152341. https://doi.org/10.1172/JCI152341